A recent study showed that knockdown of BRMS1 in mutant P53 cells in vitro significantly reduced GBM cell growth and migration/invasion by inhibiting the NF-κB signalling pathway, suggesting that BRMS1 may be a potential therapeutic marker for mutant P53 GBM [60]. The gene discussed is NFKB1; the disease is glioblastoma.